Lv6
1680 积分 2023-10-16 加入
Handing missing data using multiple imputation in hybrid control clinical trials with modified power prior
19天前
已完结
Sample sizes for randomized controlled trials utilizing Bayesian response adaptive randomization for continuous outcomes
19天前
已完结
Simulated treatment comparisons with jackknife pseudo values for estimating population-adjusted marginal treatment effects
19天前
已完结
Leveraging external controls in clinical trials: estimands, estimation, assumptions
19天前
已完结
CUI ‐ MET : A Clinical Utility Index Based Analysis and Decision Framework for Dose Optimization in Multiple‐Dose, Multiple‐Outcome Randomized Trials
19天前
已完结
Optimizing Randomization Ratios in Clinical Trials With Survival Endpoints
19天前
已完结
A Seamless Two‐Stage Phase I/II Trial Design With Backfill and Joint Monitoring for Dose Optimization
28天前
已完结
Izalontamab brengitecan (Iza-bren; BL-B01D1), a first-in-class EGFR-HER3 bispecific antibody–drug conjugate, for patients with EGFR-mutated NSCLC: pooled analysis of phase I and phase II trials
29天前
已完结
Izalontamab brengitecan (Iza-bren; BL-B01D1), a first-in-class EGFR-HER3 bispecific antibody–drug conjugate, for patients with EGFR-mutated NSCLC: pooled analysis of phase I and phase II trials
29天前
已完结
Fruquintinib versus placebo in patients with refractory metastatic colorectal cancer (FRESCO-2): an international, multicentre, randomised, double-blind, phase 3 study
1个月前
已完结
皖公网安备34019202002308
